Data demonstrated multiple clinical benefits beyond linear growth— NDA supported by data from three randomized, double-blind, ...
Ascendis Pharma (ASND) announced that it has submitted its new drug application to the FDA for TransCon CNP for the treatment of children with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback